Satellos Bioscience Inc. (MSCLF) Form 6-K — Jun 25, 2026
Satellos Bioscience announced that it will present clinical program updates for its SAT-3247 drug candidate at the 19th International Congress on Neuromuscular Diseases (ICNMD) in July 2026. The presentations will include a poster highlighting six-month follow-up data from participants who completed the Phase 1b trial and enrolled in the ongoing Phase 2 TRAILHEAD study.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.